• Intercept Announces Data to be Presented at Digestive Disease Week 2025 GlobeNewswire Wed, 30 Apr 2025 12:21:41 GMT
• ViewPoints: RP103’s failure in NASH removes a competitor on margins for Intercept, others FirstWord Pharma Tue, 29 Apr 2025 12:51:26 GMT
• Fatty Liver Treatment Market Detailed in New Research Report openPR.com Fri, 25 Apr 2025 15:34:00 GMT
• Primary Biliary Cholangitis Treatment Market Deep Research openPR.com Fri, 25 Apr 2025 07:00:00 GMT
• middle east and turkey chronic liver disease (cld) therapeutics openPR.com Thu, 24 Apr 2025 07:03:09 GMT
• Ipsen's liver disease drug Iqirvo off to promising launch in battle with Gilead's Livdelzi Fierce Pharma Thu, 17 Apr 2025 07:00:00 GMT
• KOL Views: What does REGENERATE win mean for Ocaliva and rest of NASH field? FirstWord Pharma Sun, 13 Apr 2025 23:00:16 GMT
• genfit set to start phase iii study of elafibranor in nash; sees possible 2019 launch FirstWord Pharma Fri, 11 Apr 2025 02:22:53 GMT
• physician views preview: do new nash data for obeticholic acid resonate with potential prescribers? FirstWord Pharma Sat, 22 Mar 2025 00:34:07 GMT
• gilead to buy phenex's drug programme for liver diseases, including nash FirstWord Pharma Sun, 09 Mar 2025 02:33:54 GMT
• y intercept hong kong ltd invests $258,000 in kiniksa pharmaceuticals, ltd. (nasdaq:knsa) Defense World Wed, 05 Mar 2025 10:19:44 GMT
• y intercept hong kong ltd trims stock holdings in ionis pharmaceuticals, inc. (nasdaq:ions) Defense World Tue, 04 Mar 2025 08:30:13 GMT
• y intercept hong kong ltd invests $328,000 in rhythm pharmaceuticals, inc. (nasdaq:rytm) Defense World Tue, 04 Mar 2025 08:00:00 GMT
• kol views results: ocaliva looks approvable but bar is low for competing nash therapies, says leading liver specialist FirstWord Pharma Sat, 01 Mar 2025 14:03:55 GMT
• investor alert: levi & korsinsky, llp notifies shareholders of intercept pharmaceuticals, inc. of a class action lawsuit and a lea... ACCESS Newswire Fri, 28 Feb 2025 14:02:51 GMT
• intercept pharmaceuticals, inc. to host earnings call ACCESS Newswire Thu, 27 Feb 2025 20:35:29 GMT
• Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244% Fierce Biotech Wed, 26 Feb 2025 08:00:00 GMT
• seasoned biopharmaceutical industry executives teri lawver and jerry durso appointed to altimmune board of directors Yahoo Finance Tue, 25 Feb 2025 08:00:00 GMT
• intercept’ liver disease drug fails late-stage trial, shares plunge BW Healthcare World Thu, 13 Feb 2025 18:36:35 GMT
• primary biliary cholangitis clinical trial pipeline | 20+ companies pioneering the future of treatment EIN News Thu, 13 Feb 2025 08:00:00 GMT
• inventiva tries restructuring to reach phase iii finish line in mash insights.citeline.com Tue, 11 Feb 2025 08:00:00 GMT
• eli lilly pledges $630m on olix’s phase i rna candidate for mash Yahoo Finance Tue, 11 Feb 2025 08:00:00 GMT
• primary biliary cholangitis market on the rise – what to expect by 2034 | delveinsight WICZ Mon, 10 Feb 2025 15:50:00 GMT
• mash drugs reach a meaningful tipping point for patients and investors STAT Thu, 30 Jan 2025 08:00:00 GMT
• US FDA’s Accelerated Approval Council: Bigger Role, More Transparency Coming? insights.citeline.com Mon, 27 Jan 2025 08:00:00 GMT
• biliary atresia market to expand significantly by 2034, states delveinsight report | albireo pharma, mirum pharmaceuticals Barchart Wed, 22 Jan 2025 16:31:57 GMT
• acumen pharmaceuticals announces phase 1 intercept-ad data supporting development of sabirnetug (acu193) for early alzheimer's dis... Nasdaq Thu, 09 Jan 2025 08:00:00 GMT
• fda wraps up 2024 handing out several notable regulatory decisions Dealbreaker Fri, 03 Jan 2025 08:00:00 GMT
• national trial attorneys, rosen, reminds intercept pharmaceuticals, inc. investors of important deadline in securities class actio... AccessWire Wed, 01 Jan 2025 05:22:13 GMT
• ocaliva down but not out: a timeline of fda troubles for a once-promising pbc contender Healio Tue, 31 Dec 2024 08:00:00 GMT
• FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval BioSpace Tue, 24 Dec 2024 08:00:00 GMT
• primary biliary cholangitis therapeutics market size in the 7mm was over further expected to increase by 2034, estimates delveinsi... The Globe and Mail Tue, 24 Dec 2024 07:02:59 GMT
• liver cirrhosis therapeutics market size in the 7mm was ~usd 3,100 million in 2023, is further anticipated to increase with a sigi... Barchart Tue, 24 Dec 2024 00:18:24 GMT
• primary biliary cholangitis therapeutics market size in the 7mm was over further expected to increase by 2034, estimates delveinsi... The Globe and Mail Mon, 23 Dec 2024 08:00:00 GMT
• liver cirrhosis therapeutics market size in the 7mm was ~usd 3,100 million in 2023, is further anticipated to increase with a sigi... Barchart Mon, 23 Dec 2024 08:00:00 GMT
• fda issues liver injury safety alert for pbc drug ocaliva Hep Treatment News Fri, 20 Dec 2024 08:00:00 GMT
• fda’s ocaliva blow spells changes in primary biliary cholangitis landscape insights.citeline.com Wed, 18 Dec 2024 08:00:00 GMT
• fda tracker: fda hands out atopic dermatitis approvals to galderma, organon BioSpace Wed, 18 Dec 2024 04:17:22 GMT
• non-alcoholic steatohepatitis treatment market set for 28.0% cagr growth, projected to hit $90.97 billion by 2034 |pmr Yahoo Finance UK Mon, 16 Dec 2024 12:26:00 GMT
• us fda identifies cases of liver injury after treatment with intercept's drug MSN Sat, 14 Dec 2024 02:04:08 GMT
• us fda says intercept's drug can cause liver injury in patients without scarring MSN Sat, 14 Dec 2024 01:10:30 GMT
• Intercept’s Troubled Drug Ocaliva Linked to ‘Serious Liver Injury’: FDA BioSpace Fri, 13 Dec 2024 08:00:00 GMT
• astrazeneca says andexxa will not convert to full approval, quietly reveals complete response insights.citeline.com Fri, 13 Dec 2024 08:00:00 GMT
• fda warns of ocaliva liver injury risks linked to autoimmune disorder drug AboutLawsuits.com Fri, 13 Dec 2024 08:00:00 GMT
• us fda identifies cases of liver injury after treatment with intercept's ocaliva (obeticholic acid) DrugsControl.org Fri, 13 Dec 2024 02:05:18 GMT
• fda warns of deaths, serious liver injury tied to incorrect dosing of intercept's ocaliva FirstWord Pharma Fri, 13 Dec 2024 01:30:28 GMT
• ocaliva linked to liver failure in more patients with pbc FirstWord Pharma Fri, 13 Dec 2024 01:18:37 GMT
• us fda says intercept's drug can cause liver injury in patients without scarring MSN Fri, 13 Dec 2024 00:58:18 GMT
• fda reports serious liver injury in patients without cirrhosis using obeticholic acid to treat pbc Pharmacy Times Thu, 12 Dec 2024 18:44:36 GMT
• FDA flags additional injury risk for Intercept’s liver drug BioPharma Dive Thu, 12 Dec 2024 08:00:00 GMT
• US FDA identifies cases of liver injury after treatment with Intercept's drug Reuters Thu, 12 Dec 2024 08:00:00 GMT
• Ocaliva linked to liver failure in more patients with PBC FirstWord Pharma Thu, 12 Dec 2024 08:00:00 GMT
• FDA: Ocaliva still linked to ‘serious liver injury’ in PBC, even without cirrhosis Healio Thu, 12 Dec 2024 08:00:00 GMT
• 'serious liver injury' cases lead fda to call for monitoring of ocaliva patients Endpoints News Thu, 12 Dec 2024 08:00:00 GMT
• could another us fda safety alert foreshadow withdrawal of intercept’s ocaliva? News & Insights Thu, 12 Dec 2024 08:00:00 GMT
• highlighting the danger of sci progression during ittp remission, with shruti chaturvedi, mbss, ms MD Magazine Mon, 09 Dec 2024 22:02:10 GMT
• alcoholic hepatitis market report 2034: epidemiology data, pipeline therapies, latest fda, ema, pdma approvals by delveinsight | d... Barchart Mon, 09 Dec 2024 08:00:00 GMT
• pbc therapy ocaliva pulled from eu market with court decision Liver Disease News Wed, 04 Dec 2024 08:00:00 GMT
• After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe Fierce Pharma Mon, 02 Dec 2024 08:00:00 GMT
• advanz pharma’s liver disease drug pulled from european market after court hearing Pharmaceutical Technology Thu, 28 Nov 2024 08:00:00 GMT
• Ocaliva officially yanked from European markets after regulatory back-and-forth FirstWord Pharma Wed, 27 Nov 2024 08:00:00 GMT
• Court sides with EU on decision to revoke Ocaliva's license pharmaphorum Wed, 27 Nov 2024 08:00:00 GMT
• non-alcoholic steatohepatitis (nash) treatment market 2032: clinical trials, medication, ema, pdma, fda approvals, epidemiology, t... The Globe and Mail Fri, 22 Nov 2024 08:00:00 GMT
• astrazeneca’s andexxa could be headed for withdrawal after us fda’s negative advisory committee preview Citeline News & Insights Wed, 20 Nov 2024 08:00:00 GMT
• us fda declines full approval for intercept's liver disease drug MSN Wed, 20 Nov 2024 05:22:41 GMT
• non-alcoholic steatohepatitis treatment market projected to show strong growth openPR Tue, 19 Nov 2024 11:10:00 GMT
• gsk scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market Fierce Biotech Tue, 19 Nov 2024 08:00:00 GMT
• us fda declines full approval for intercept's liver disease drug MSN Mon, 18 Nov 2024 14:50:07 GMT
• global non-alcoholic steatohepatitis market outlook 2024-2032: m WICZ Mon, 18 Nov 2024 08:00:00 GMT
• kris kowdley, md: elafibranor improves long-term transplant-free survival in pbc HCPLive Sun, 17 Nov 2024 08:00:00 GMT
• rx rundown: roche, metsera, intercept pharmaceuticals and more MM+M Online Fri, 15 Nov 2024 08:00:00 GMT
• us fda declines full approval for intercept's liver disease drug MSN Thu, 14 Nov 2024 19:30:36 GMT
• fda rejects ocaliva approval for liver disease treatment Evrim Ağacı Wed, 13 Nov 2024 19:58:02 GMT
• US FDA declines full approval for Intercept's liver disease drug Reuters Wed, 13 Nov 2024 08:00:00 GMT
• Intercept loses Ocaliva FDA full approval bid in rare liver disease Pharmaceutical Technology Wed, 13 Nov 2024 08:00:00 GMT
• Full approval of Ocaliva as second-line PBC treatment fails to win... Liver Disease News Wed, 13 Nov 2024 08:00:00 GMT
• fda rejects full approval of ocaliva as second-line pbc treatment Liver Disease News Wed, 13 Nov 2024 08:00:00 GMT
• FDA rejects Intercept's ask for Ocaliva full nod in rare liver disease, but accelerated approval remains Fierce Pharma Tue, 12 Nov 2024 08:00:00 GMT
• Ocaliva denied full approval for PBC, but gets to stay on the market — for now FirstWord Pharma Tue, 12 Nov 2024 08:00:00 GMT
• Intercept is denied full FDA approval for Ocaliva, but claims it will keep drug on market Endpoints News Tue, 12 Nov 2024 08:00:00 GMT
• FDA denies Ocaliva full approval in primary biliary cholangitis; safety data still in play Healio Tue, 12 Nov 2024 08:00:00 GMT
• fda issues crl to obeticholic acid (ocaliva), denies full approval for pbc MD Magazine Tue, 12 Nov 2024 08:00:00 GMT
• us fda declines full approval for intercept’s liver disease drug PharmaLive Tue, 12 Nov 2024 08:00:00 GMT
• fda takes step toward removal of ineffective decongestants from the market MedCity News Fri, 08 Nov 2024 08:00:00 GMT
• [interview] jd bioscience advances dual-action nash drug as industry giants falter koreabiomed.com Fri, 01 Nov 2024 07:00:00 GMT
• j.p. morgan day 4: setting goals for the year ahead insights.citeline.com Thu, 24 Oct 2024 18:43:05 GMT
• Full approval on Ocaliva for primary biliary cholangitis delayed Liver Disease News Wed, 23 Oct 2024 07:00:00 GMT
• Intercept’s liver disease drug Ocaliva faces FDA approval delay Pharmaceutical Technology Sat, 19 Oct 2024 07:00:00 GMT
• ptc rebuffed again by ema; novartis licenses china-based biotech’s cancer drug Yahoo Finance Fri, 18 Oct 2024 07:00:00 GMT
• after ocaliva: us fda sees breakthrough potential in new approaches to liver disease insights.citeline.com Fri, 18 Oct 2024 07:00:00 GMT
• intercept’s liver disease drug ocaliva faces fda approval delay Yahoo Finance Fri, 18 Oct 2024 07:00:00 GMT
• intercept provides regulatory update regarding snda for ocaliva GlobeNewswire Thu, 17 Oct 2024 07:00:00 GMT
• fda needs more time to decide on intercept’s ocaliva The Pharma Letter Thu, 17 Oct 2024 07:00:00 GMT
• fda extends review of obeticholic acid (ocaliva) snda for primary biliary cholangitis MD Magazine Thu, 17 Oct 2024 07:00:00 GMT
• intercept’s liver disease drug faces full approval delay following negative adcomm Endpoints News Thu, 17 Oct 2024 07:00:00 GMT
• intercept pharmaceuticals, inc. provides regulatory update regarding snda for ocaliva Marketscreener.com Thu, 17 Oct 2024 07:00:00 GMT
• Drug-Sniffing Police Dogs Are Intercepting Abortion Pills in the Mail The Intercept Wed, 16 Oct 2024 07:00:00 GMT
• pfizer invests in molecular glue; jazz, meiragtx shares rise on drug data Yahoo Finance Tue, 15 Oct 2024 07:00:00 GMT
• amid shifting mash landscape, inventiva adds €348m financing BioWorld Online Tue, 15 Oct 2024 07:00:00 GMT
• ocaliva exit could help ipsen and gilead’s new cholangitis entrants Scrip Mon, 14 Oct 2024 19:17:23 GMT
• Mark Pruzanski gets another shot at MASH, joining as chair of Inventiva as it gets ‘much-needed funding’ Endpoints News Mon, 14 Oct 2024 07:00:00 GMT
• FDA gets drugs out faster, but some work only ‘marginally’ better and are more expensive Daily Montanan Sun, 13 Oct 2024 07:00:00 GMT
• primary biliary cholangitis market growth to accelerate in forecast period (2024-2034), delveinsight analyzes | intercept pharma, ... The Globe and Mail Thu, 10 Oct 2024 14:38:00 GMT
• drug rivals face off in pbc after fda hands down 2 new approvals, 1 advisory snub Healio Thu, 10 Oct 2024 07:00:00 GMT
• intercept pharmaceuticals (icpt) price target increased by 6.63% to 19.38 MSN Wed, 09 Oct 2024 07:14:15 GMT
• mhra clears iqirvo as first medicine for rare liver disease The Pharma Letter Tue, 08 Oct 2024 07:00:00 GMT
• intercept pharmaceuticals (icpt) price target increased by 21.49% to 18.17 MSN Thu, 03 Oct 2024 10:17:41 GMT
• border officers intercept 'poisonous' narcan-resistant drug xylazine Newsweek Tue, 01 Oct 2024 07:00:00 GMT
• sponsors aim to avoid confirmatory trial hurdles that plagued ocaliva in primary biliary cholangitis Citeline News & Insights Tue, 01 Oct 2024 07:00:00 GMT
• us fda's slim october user fee calendar brings some controversy Pink Sheet Mon, 30 Sep 2024 23:23:56 GMT
• ipsen’s iqirvo wins european approval for primary biliary cholangitis MSN Fri, 27 Sep 2024 12:10:47 GMT
• expert reviews findings from the auriga study in myeloma Pharmacy Times Fri, 27 Sep 2024 07:00:00 GMT
• intercept’s ocaliva falls at us fda panel; is accelerated approval withdrawal on the horizon? Pink Sheet Fri, 27 Sep 2024 05:25:25 GMT
Intercept Pharmaceuticals, Inc(NASDAQ:ICPT) 
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for t...
Website: http://www.interceptpharma.com
Founded: 2002
IPO Price: $15 (Oct 11, 2012)
Full Time Employees: 583
CEO: Jerry Durso
Sector: Healthcare
Industry: Biotechnology